Viatris makes generic and off-patent branded drugs.
Viatris Inc. (VTRS) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 07:53 ET. Consensus EPS estimate is $0.67.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | FY2026 Q2 | $0.60 | $0.69 | +14.8% | $3.76B |
| 2026-05-07 | FY2026 Q1 | $0.50 | $0.59 | +17.5% | $3.52B |
| 2026-02-26 | FY2025 Q4 | $0.53 | $0.57 | +7.1% | $3.70B |
| 2025-11-06 | FY2025 Q3 | $0.62 | $0.67 | +7.9% | $3.76B |
| 2025-08-07 | FY2025 Q2 | $0.56 | $0.62 | +11.5% | $3.58B |
| 2025-05-08 | FY2025 Q1 | $0.49 | $0.50 | +1.6% | $3.25B |
| 2025-02-27 | FY2024 Q4 | $0.61 | $0.54 | -11.5% | $3.53B |
| 2024-11-07 | FY2024 Q3 | $0.68 | $0.75 | +10.8% | $3.74B |
VTRS has beaten consensus EPS in 7 of its last 8 reported quarters.
VTRS reported Aug 6. The highlights: EPS of $0.69 — a beat vs the $0.60 estimate (+15%); revenue of $3.76B — a beat vs the $3.68B consensus (+2%).
VTRS pays a quarterly dividend, currently yielding 2.94%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-08-21 | $0.12 | 2026-09-16 |
| 2026-05-22 | $0.12 | 2026-06-17 |
| 2026-03-09 | $0.12 | 2026-03-18 |
| 2025-11-24 | $0.12 | 2025-12-15 |
| 2025-08-22 | $0.12 | 2025-09-15 |
| 2025-05-23 | $0.12 | 2025-06-16 |